India Large Volume Parenteral Market Outlook 2031:
The India large volume parenteral market size was valued at USD 100.04 Million in 2022 and is projected to reach USD 67.59 Million by 2031, expanding at a CAGR of 5.9% during the forecast period 2023 - 2031. The growth of the market is attributed to the rise in local manufacturing towards large volume parenteral over importing from other countries.
Large parenteral solutions are intravenous solutions which are sold in bottles or bags which contain specific volumes as per the requirements of the hospital or the patients. Every large parenteral solutions need to correct their fluid and electrolyte imbalances which can in turn provide the required nutrients or act similar to a carrier of the delivery for other drugs.
In India, there is a large population of children under malnutrition, rising rate of premature births, high natality, and rising occurrences of cancer which all benefit heavily from large parenteral solutions.
According to the Census of India in 2019, 20% of the population fall under patients of diseases such as esophageal cancer, Crohn’s, gastric cancer, neck & head cancer, laryngeal cancer, and ulcerative colitis. The common factor for these diseases is not only that they are fatal, but also the fact that intake of food from an oral perspective is impossible.
The only way to treat these patients is through parenteral solutions. The COVID-19 pandemic has impacted positively towards the market growth due to the rising adoption of large volume parenteral solutions for numerous applications and rising doctor’s preference to the single-dose administration of drugs which can improve the drug absorption thereby leading to a safer and faster recovery for the patients.
There is the increasing occurrences of chronic diseases which is proportionate to the increase in the geriatric population who are all reliant on large volume parenteral solutions. The COVID-19 pandemic has also resulted in the increase of the spread of other chronic diseases which requires large number of surgeries and all these function upon large volume parenteral solutions.
India Large Volume Parenteral Market Trends, Drivers, Restraints, and Opportunities
- Increase in spending and investing by key companies towards the development of new volume parenteral solutions is a primary reason to boost the market growth during the forecast period.
- Rapid growth of the biopharmaceutical companies and thereby that industry can become a major factor in the boosting of the India large volume parenteral market during the forecast period.
- High prices for the development of large volume parenteral solutions and high cost of services from the company’s perspective is anticipated to hinder the India market growth.
- Large volume parenteral solutions need to be administered by medical authorities or through special licenses for home care support. The requirement needed for these solutions can never be met by the suppliers because of the medical restrictions that impose to this drug delivery. This can hamper the market growth.
- R&D investment and technological advancement are expected to offer significant opportunities for the market players. The Indian Government have undertaken several steps for the reduction of overall healthcare expenditure & medical costs which includes safely automated delivery systems & drug mixtures.
Scope of the India Large Volume Parenteral Market Report
The report on the India large volume parenteral market size includes an assessment of the market, trends, segments, and regional markets. Overview and dynamics have also been included in the report.
Large Volume Parenteral Market- India Industry Analysis, Growth, Share, Size, Trends, and Forecast
Applications (Therapeutic Injections, Fluid Balance Injections, and Nutritious Injections), Volumes (100 ml, 250 ml, 500 ml, 1000 ml, and 2000 ml), and End-Users (Hospitals & Other Healthcare Facilities and Home Care)
North, South, East, and West
Company Share, Market Analysis and Size, Competitive Landscape, Growth Factors, Trends, and Revenue Forecast
Key Players Covered in the Report
Grifols; B. Braun Melsungen AG; Fresenius Kabi AG; Baxter; Otsuka Pharmaceuticals; Sitchuan Kelun; Albert David Ltd.; and BML Parenteral Drugs
India Large Volume Parenteral Market Segment Insights
Nutritious injections segment is projected to represent a large market share
Based on applications, the India large volume parenteral market is divided into therapeutic injections, fluid balance injections, and nutritious injections. The nutritious injections segment constituted a major market share of 47% in 2019. The major reason for the segment growth is the rise in demand of formulations pertaining to nutritious injections which can improve drug absorption leading to effective and faster results.
Meanwhile the therapeutic injections segment is anticipated to expand at a significant CAGR during the forecast period, 2021-2028. This is attributed to the rise in life-threatening diseases which leads to increasing demand for faster, effective, and safer methods for drug administration which is provided by therapeutic injections.
500ml segment is anticipated to register a large market share
On the basis of volumes, the India large volume parenteral market is divided into 100 ml, 250 ml, 500 ml, 1000 ml, and 2000 ml. The 500 ml segment constituted a major market share of 34.1% in 2019.
The major reason for the segment growth is the use of these measures by a number of health care professionals for multiple surgeries, single-dose drug & vaccine administration, and hospital-associated malnutrition. For all these processes, 500 ml is the adequate amount of parenteral solutions required.
Meanwhile the 100 ml segment is anticipated to expand at a significant CAGR during the forecast period, 2021-2028. This is attributed to the further research studies about the limited use of large volume parenteral solutions. Researchers and scientists have understood that 100 ml is the perfect amount of solutions administration required for people weighing under 50 kg, which is most of the malnutrition population.
Hospitals & other healthcare facilities segment is expected to register a large market share
Based on end-users, the India large volume parenteral market is bifurcated into hospitals & other healthcare facilities and home care. The hospitals & other healthcare facilities segment constituted a major market share of 97.6% in 2019.
The major reason for the segment growth is the rise in demand for these solutions for drug & vaccine administration for patients and for the patients undergoing surgeries. These functions can only be done in hospitals for maximum efficiency and facilities provided by them.
Meanwhile the home care segment is anticipated to expand at a significant CAGR during the forecast period, 2021-2028. This is attributed to the rising consumer preference towards especially during the COVID-19 pandemic, where the hospital infected diseases have risen exponentially.
New developments amongst physicians have made all facilities available for treating any diseases & difficulties faced by the patient with the required supply of large volume parenteral solutions.
The India large volume parenteral market size has been segmented in terms of
- Therapeutic Injections
- Fluid Balance Injections
- Nutritious Injections
- 100 ml
- 250 ml
- 500 ml
- 1000 ml
- 2000 ml
- Hospitals & Other Healthcare Facilities
- Home Care
Major players competing in the India large volume parenteral market are Grifols; B. Braun Melsungen AG; Fresenius Kabi AG; Baxter; Otsuka Pharmaceuticals; Sitchuan Kelun; Albert David Ltd.; and BML Parenteral Drugs.
These market players are involved in several business strategies such as mergers, acquisitions partnerships, collaborations, capacity expansion, and product launches to enhance their market shares.
In 2017, Baxter acquired Claris Injectables which is a division of a company called Claris Lifesciences which added Baxter’s production abilities towards generic intravenous solutions & injectables and thereby increased their market share to more than half. In 2019, Baxter acquired the entire company of Claris Lifesciences.